My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 132

    1.

    Varenicline and bupropion sustained-release combination therapy for smoking cessation.

    Ebbert JO, Croghan IT, Sood A, Schroeder DR, Hays JT, Hurt RD.

    Nicotine Tob Res. 2009 Mar;11(3):234-9. Epub 2009 Feb 25.PMID: 19246427 [PubMed - indexed for MEDLINE]Related articles

    2.

    Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

    Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR; Varenicline Phase 3 Study Group.

    JAMA. 2006 Jul 5;296(1):47-55.PMID: 16820546 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

    Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR; Varenicline Phase 3 Study Group.

    JAMA. 2006 Jul 5;296(1):56-63. Erratum in: JAMA. 2006 Sep 20;296(11):1355. PMID: 16820547 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Varenicline: a first-line treatment option for smoking cessation.

    Garrison GD, Dugan SE.

    Clin Ther. 2009 Mar;31(3):463-91. Review.PMID: 19393839 [PubMed - indexed for MEDLINE]Related articles

    5.

    A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations.

    Robles GI, Singh-Franco D, Ghin HL.

    Clin Ther. 2008 May;30(5):800-12. Review.PMID: 18555928 [PubMed - indexed for MEDLINE]Related articles

    6.

    Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist.

    Tonstad S.

    J Cardiovasc Nurs. 2006 Nov-Dec;21(6):433-6.PMID: 17293731 [PubMed - indexed for MEDLINE]Related articles

    7.

    Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.

    Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, Reeves KR.

    Arch Intern Med. 2006 Aug 14-28;166(15):1561-8.PMID: 16908788 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants.

    Chengappa KN, Kambhampati RK, Perkins K, Nigam R, Anderson T, Brar JS, Vemulapalli HK, Atzert R, Key P, Kang JS, Levine J.

    J Clin Psychiatry. 2001 Jul;62(7):503-8.PMID: 11488359 [PubMed - indexed for MEDLINE]Related articles

    9.

    Varenicline: a review of its use as an aid to smoking cessation therapy.

    Keating GM, Siddiqui MA.

    CNS Drugs. 2006;20(11):945-60. Review.PMID: 17044731 [PubMed - indexed for MEDLINE]Related articles

    10.

    Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial.

    Aubin HJ, Bobak A, Britton JR, Oncken C, Billing CB Jr, Gong J, Williams KE, Reeves KR.

    Thorax. 2008 Aug;63(8):717-24. Epub 2008 Feb 8.PMID: 18263663 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers.

    Tsai ST, Cho HJ, Cheng HS, Kim CH, Hsueh KC, Billing CB Jr, Williams KE.

    Clin Ther. 2007 Jun;29(6):1027-39.PMID: 17692719 [PubMed - indexed for MEDLINE]Related articles

    12.

    A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.

    Evins AE, Cather C, Culhane MA, Birnbaum A, Horowitz J, Hsieh E, Freudenreich O, Henderson DC, Schoenfeld DA, Rigotti NA, Goff DC.

    J Clin Psychopharmacol. 2007 Aug;27(4):380-6.PMID: 17632223 [PubMed - indexed for MEDLINE]Related articles

    13.

    Varenicline: a novel pharmacotherapy for smoking cessation.

    Jiménez-Ruiz C, Berlin I, Hering T.

    Drugs. 2009;69(10):1319-38. doi: 10.2165/00003495-200969100-00003. Review.PMID: 19583451 [PubMed - indexed for MEDLINE]Related articles

    14.

    Which is the best primary medication for long-term smoking cessation--nicotine replacement therapy, bupropion or varenicline?

    Doggrell SA.

    Expert Opin Pharmacother. 2007 Dec;8(17):2903-15. Review.PMID: 18001252 [PubMed - indexed for MEDLINE]Related articles

    15.

    Systematic review and meta-analysis of combination therapy for smoking cessation.

    Shah SD, Wilken LA, Winkler SR, Lin SJ.

    J Am Pharm Assoc (2003). 2008 Sep-Oct;48(5):659-65. Review.PMID: 18826906 [PubMed - indexed for MEDLINE]Related articles

    16.

    Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt.

    West R, Baker CL, Cappelleri JC, Bushmakin AG.

    Psychopharmacology (Berl). 2008 Apr;197(3):371-7. Epub 2007 Dec 15.PMID: 18084743 [PubMed - indexed for MEDLINE]Related articles

    17.

    Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.

    Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, Anziano R, Reeves K.

    Arch Intern Med. 2006 Aug 14-28;166(15):1571-7.PMID: 16908789 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Late-term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo.

    Jamerson BD, Nides M, Jorenby DE, Donahue R, Garrett P, Johnston JA, Fiore MC, Rennard SI, Leischow SJ.

    Clin Ther. 2001 May;23(5):744-52.PMID: 11394732 [PubMed - indexed for MEDLINE]Related articles

    19.

    Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers.

    Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR.

    Clin Ther. 2007 Jun;29(6):1040-56.PMID: 17692720 [PubMed - indexed for MEDLINE]Related articles

    20.

    A preliminary benefit-risk assessment of varenicline in smoking cessation.

    Cahill K, Stead L, Lancaster T.

    Drug Saf. 2009;32(2):119-35. doi: 10.2165/00002018-200932020-00005. Review.PMID: 19236119 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity